The Cyclin D1-dependent Kinase Associates with the
Pre-replication Complex and Modulates RB·MCM7 Binding*
Andrew B.
Gladden and
J. Alan
Diehl
From the Leonard and Madlyn Abramson Family Cancer Research
Institute, Department of Cancer Biology, Abramson Family Cancer
Center of the University of Pennsylvania,
Philadelphia, Pennsylvania 19104
Received for publication, November 27, 2002, and in revised form, December 23, 2002
 |
ABSTRACT |
The capacity of the cyclin
D-dependent kinase to promote G1 progression
through modulation of RB·E2F is well documented. We now
demonstrate that the cyclin D1/CDK4 kinase binds to components of the
MCM complex. MCM7 and MCM3 were identified as cyclin D1-binding proteins. Catalytically active cyclin D1/CDK4 complexes were
incorporated into chromatin-bound protein complexes with the same
kinetics as MCM7 and MCM3, where they associated specifically with
MCM7. Although the cyclin D1-dependent kinase did not
phosphorylate MCM7, active cyclin D1/CDK4, but not cyclin E/CDK2, did
catalyze the dissociation of an RB·MCM7 complex. Finally, expression
of an active D1/CDK4 kinase but not cyclin E/CDK2 promoted the removal of RB from chromatin-bound protein complexes. Our data suggest that
D1/CDK4 complexes play a direct role in altering an inhibitory RB·MCM7 complex possibly allowing for setting of the origin in preparation for DNA replication.
 |
INTRODUCTION |
External stimuli activate cellular signaling cascades, thereby
promoting the induction of cellular activities needed to initiate DNA
replication. During the G1 phase, growth factor-initiated signals promote the accumulation and assembly of the D-type cyclins (D1, D2, D3) with their cognate cyclin-dependent kinase
(CDK41 or 6). The active
holoenzyme promotes G1 phase progression and S phase entry
by virtue of its ability to phosphorylate the retinoblastoma protein
(RB) and titrate the CDK inhibitors p27Kip1 and
p21Cip1 (1, 2). Initial phosphorylation of RB and titration
of the CDK inhibitors expedites the activation of the cyclin E/CDK2 kinase, thereby completing RB phosphorylation and inactivation prior to
initiation of DNA replication.
Initiation of DNA replication at the G1/S phase boundary is
meticulously regulated to ensure the cell has assembled the appropriate machinery needed for high fidelity genome duplication. Prior to S phase
entry, pre-replication complexes (pre-RC) form at replication origins
during G1 phase. Origins are first marked by the origin recognition complex (ORC), which is composed of six subunits (ORC1-6) (3) and serves as a landing pad for recruitment of the DNA replication
machinery (4). Following ORC binding, CDC6 (5) and Cdt1 (6) associate
and function to recruit the minichromosome maintenance proteins (MCM),
a group of highly conserved proteins essential for the initiation of
DNA synthesis (7-9). The MCM complex is composed of six distinct, but
related polypeptides, MCM2, MCM3, MCM4, MCM5, MCM6, and MCM7 (10), that
form a hexameric helicase the activity of which is essential for
initiation and elongation of the replication fork (11). Origin firing
at the G1/S boundary is also highly regulated, but the
precise regulatory mechanisms remain unclear. Both cyclin E/CDK2 and a
distinct kinase composed of Cdc7 and Dbf4 function to promote S phase
entry, perhaps through direct phosphorylation of MCM subunits
(12-16).
Although current data support the notion that the phosphorylation
status of pre-RC subunits determines activity, it is also becoming
clear that interactions with cell cycle inhibitors also contribute. The
RB tumor suppressor protein functions as the primary block that
prevents premature activation of cell cycle entry and thus premature S
phase entry. Although the cell cycle inhibitory activity of RB is most
thoroughly understood in terms of its ability to directly repress
E2F-dependent transcription (17), RB also directly
associates with the pre-RC through MCM7 (18) and perhaps subunits of
ORC (19).
Given that RB associates with components of the pre-RC and that RB is
the only known substrate of cyclin D1, we considered the possibility
that cyclin D1 might target components of the DNA replication machinery
that are inhibited by RB. Using cyclin D1 as bait for a yeast
two-hybrid screen, we identified MCM7 as a cyclin D1 binding partner.
We demonstrate that cyclin D1 mediates binding of the cyclin D1/CDK4
complex to MCM7 in mammalian cells. We demonstrate that the cyclin
D1/CDK4 kinase is incorporated into chromatin-bound protein complexes,
with the same kinetics as MCM7 and that the cyclin D1/CDK4 kinase
specifically dissociates RB·MCM7 complexes, thereby facilitating
establishment of the pre-RC.
 |
EXPERIMENTAL PROCEDURES |
Yeast Two-hybrid Screen--
Yeast strain Y190 (his3 leu2
trp1), which carries GAL4-dependent lacZ
and HIS3 genes, was transformed with pAS2D1, and
TRP+ transformants were examined for lacZ and
HIS3 expression via a
-galactosidase assay and growth on
media lacking histidine. A lacZ
HIS3
TRP1+ clone was
transformed with a HEK293 cDNA library
(Clontech) fused to the GAL4 activation domain in
plasmid pGAD-GH, a LEU2 yeast plasmid. Transformants were
replica plated onto indicator plates to score for growth in media
lacking histidine and
-galactosidase activity. This selection
resulted in 51 positive colonies. Further analysis revealed that the
cDNAs encoded by each of the 51 colonies interacted with GAL4-D1
and not other bait constructs containing GAL4 fusions with p53 or large
T antigen.
Cell Culture Conditions and Transfections--
NIH-3T3 cells and
RB
/
mouse embryonic fibroblasts (MEFs) were maintained in
Dulbecco's modified Eagle's medium containing glutamine supplemented
with antibiotics (BioWhittaker) and 10% fetal calf serum
(BioWhittaker). Derivatives of NIH-3T3 cells engineered to overexpress
Flag-tagged cyclin D1 and Flag-tagged cyclin D1-T286A have been
described previously (20). Insect Sf9 cells were grown in
Grace's medium supplemented with 10% heat-inactivated fetal calf
serum. Procedures for manipulation of baculoviruses have been described
previously (21). Transient expression of plasmids encoding HA-tagged
MCM7, Flag-tagged cyclin D1, CDK4, RB, CDK4/K35M, Myc-tagged cyclin E,
and CDK2 was achieved by using LipofectAMINE Plus (Invitrogen)
according to the instructions from the manufacturer.
Purification of Active Cyclin-CDK Complexes--
Following
infection of insect Sf9 cells with the indicated viral
supernatants, cells were lysed in Tween 20 buffer (50 mM HEPES (pH 8), 150 mM NaCl, 2.5 mM EGTA, 1 mM EDTA, 0.1% Tween 20) and cleared by sedimentation for
10 min. Flag-D1 complexes were purified by affinity chromatography
using M2-agarose (Sigma) and eluted with FLAG peptide (5 µg/ml)
(Sigma) solubilized in kinase buffer (50 mM HEPES (pH 8),
10 mM MgCl2, 2.5 mM EGTA, 1 mM dithiothreitol, 20 µM ATP, 10 mM
-glycerol phosphate, 0.1 mM
NaVO3, and 1 mM NaF). Cyclin E/His-CDK2
complexes were purified using TALON metal affinity resin
(Clontech) and eluted with 150 mM
imidazole solubilized in His-CDK2 kinase buffer (50 mM HEPES (pH 8), 10 mM MgCl2, 1 mM dithiothreitol, 20 µM ATP, 10 mM
-glycerol phosphate, 0.1 mM
NaVO3, and 1 mM NaF). Purified complexes were either used immediately or stored at 4 °C.
Chromatin-binding Assays--
Cells harvested by trypsinization
were lysed in CSK+ buffer (10 mM Pipes (pH 7.0), 100 mM NaCl, 300 mM sucrose, 3 mM
MgCl2, 0.5% Triton X-100, 1 mM ATP, 0.1 mM phenylmethylsulfonyl fluoride, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml pepstatin, and 25 mM
-glycerol phosphate). Lysates were incubated on ice for 20 min and
then subjected to low speed centrifugation (1000 × g) for 5 min. The soluble fraction was removed, and the chromatin pellet
was washed one time with DNase I buffer and then digested with DNase I
to release chromatin-bound proteins. Soluble and chromatin fractions
were then used for direct Western or co-immunoprecipitation analysis,
as directed in the figure legends. Subsequently, proteins were resolved
electrophoretically on denaturing polyacrylamide gels and transferred
to nitrocellulose. Membranes were blotted with antibodies specific for
cyclin D1 (D1-17-13G or Oncogene Research Products, Ab-3), CDK4 (Santa
Cruz Biotechnologies, sc-260), MCM7 (U. S. Biological, C2563), or MCM3
(Santa Cruz Biotechnologies, sc-9850). Antibody binding was visualized
using protein-conjugated horseradish peroxidase (HRP, EY Laboratories),
anti-mouse-conjugated HRP (Dako), or anti-rabbit-conjugated HRP
(Amersham Biosciences).
In Vitro Binding and Immunoprecipitation--
MCM proteins were
synthesized using coupled in vitro transcription and
translation in rabbit reticulocyte lysates (Promega) in the presence of
[35S]methionine and mixed with Sf9 lysates
containing FLAG-D1. Complexes were collected with the anti-FLAG M2
monoclonal antibody (Sigma). Precipitated complexes were washed four
times with Tween 20 IP buffer and resolved on denaturing polyacrylamide gels.
For detection of complexes formed in Sf9 insect cells, cells
infected with the indicated viruses were lysed in Tween 20 IP buffer.
Complexes were collected with antibodies specific to one component of
the complex of interest and protein A-Sepharose (Amersham Biosciences).
Antibody-protein complexes were washed three times with Tween 20 IP
buffer, resolved on denaturing polyacrylamide gels, and
electrophoretically transferred to nitrocellulose membranes (Millipore). For detection of cyclin D1·MCM7 protein complexes in
mammalian cells, cells were harvested in CSK+ buffer (as described above) and fractions containing soluble or chromatin-bound protein were
each subjected to precipitation with the cyclin D1 monoclonal antibody
(D1-17-13G) and protein A-Sepharose. Complexes were resolved by
SDS-PAGE, and proteins were detected by immunoblot analysis with either
the cyclin D1 antibody or an MCM7 antibody. Sites of antibody binding
were visualized with either protein-conjugated HRP (EY Laboratories),
anti-mouse-conjugated HRP (Dako), or anti-rabbit-conjugated HRP
(Amersham Biosciences).
Protein Kinase Assays and Immunofluorescence--
For detection
of cyclin D1-dependent kinase activity with chromatin-bound
cyclin D1/CDK4, cells were harvested in CSK+ buffer and diluted into
Tween 20 IP buffer and precipitated with the cyclin D1 monoclonal
antibody (D1-17-13G). Protein kinase assays using 1 µg of
recombinant GST-RB were performed as previously described (22). For
immunofluorescence, NIH-3T3 were seeded on glass coverslips and
transfected with expression vectors encoding the indicated DNAs. Whole
cells were fixed 36 h following transfection using 3%
paraformaldehyde. Cells demonstrating chromatin-bound protein were
treated with CSK+ buffer for 30 min and fixed with 3%
paraformaldehyde. For DNase I treatment, transfected cells were treated
with CSK+ buffer for 30 min and then digested with 200 units/ml DNase I
(Promega) for 25 min prior to fixation. Flag-D1 was visualized with the
M2 monoclonal antibody (Sigma), and Myc-tagged cyclin E was visualized
with the 9E10 monoclonal antibody followed by biotinylated anti-mouse
and subsequently streptavidin Texas Red. MCM7 was visualized using a
polyclonal rabbit anti-MCM7 (PharMingen) followed by fluorescein
isothiocyanate-conjugated anti-rabbit (Amersham Biosciences). RB was
visualized using a polyclonal rabbit anti-RB (Santa Cruz
Biotechnologies, sc-50-G) followed by fluorescein isothiocyanate-conjugated anti-rabbit. DNA was visualized using Hoechst
33258 dye. Coverslips were mounted on glass slides with Vectashield
mounting medium (Vector Laboratories).
 |
RESULTS |
Cyclin D1 Binds to the Carboxyl Terminus of MCM7--
We utilized
a yeast two-hybrid screen to identify novel interacting partners for
cyclin D1. pAS2-D1, which encodes full-length murine cyclin D1 fused in
frame with the GAL4 DNA-binding domain, was transformed into the yeast
strain, Y190, which carries a GAL4-dependent lacZ gene. Yeast expressing only pAS2-D1 were devoid of
-galactosidase activity as determined by their ability to drive
lacZ expression and were deemed suitable for yeast
two-hybrid analysis. Yeast expressing pAS2-D1 were co-transformed with
a 293 cDNA library fused to the GAL4 activation domain.
Transformants were replica-plated onto indicator plates and scored for
growth in the absence of histidine and tryptophan and for
-galactosidase activity. Fifty-one positive clones were identified,
and each clone was found to interact specifically with cyclin D1 but
not GAL4 fusion proteins such as p53 or large T-antigen (data not
shown). Sequence analysis revealed one candidate cDNA to encode the
carboxyl-terminal 132 residues of MCM7, a member of the MCM family of
proteins (Fig. 1A) (23).

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 1.
Cyclin D1 binds to the COOH terminus of
MCM7. A, predicted amino acid sequence, corresponding
to residues 587-719, of the MCM7 cDNA identified in a cyclin D1
yeast two-hybrid screen. B, cyclin D1 binds specifically to
MCM7 in vitro. MCM2-7 were labeled with
[35S]methionine by in vitro transcription and
translation. Labeled proteins were mixed with Sf9 lysates
programmed with Flag-D1 and immunoprecipitated with control rabbit
serum (NRS) or with the M2 monoclonal antibody. Ten percent
of the MCM proteins mixed with Flag-D1 were resolved by SDS-PAGE
(lower panel). MCM proteins were visualized by
autoradiography.
|
|
MCM7 is a component of a hexameric helicase that associates with
chromatin in G1 phase prior to initiation of DNA
replication and dissociates progressively during S phase (8, 11). The MCM complex contains six unique, yet homologous family members, MCM2-7, three of which possess intrinsic helicase activity (10, 24-26). To assess the ability of MCM7 and other MCM family members to
directly associate with cyclin D1, individual MCM proteins were
in vitro transcribed and translated in the presence of
[35S]methionine and mixed with recombinant Flag-tagged
cyclin D1. Complexes were precipitated with a cyclin D1-specific
antibody and separated on a denaturing polyacrylamide gel, and MCM
association with cyclin D1 was assessed by autoradiography. Although
MCM7 co-purified with cyclin D1 (Fig. 1B, lane
7), MCM2-6 binding was at or below background levels (Fig.
1B, lanes 2-6). Cyclins D2 and D3
were also found to associate with MCM7 (data not shown).
To independently assess potential interactions between cyclin D1 and
MCM family members, insect Sf9 cells were co-infected with
baculoviruses encoding Flag-tagged cyclin D1 along with MCM2, MCM3,
MCM6, or MCM7. Lysates prepared from these cells were precipitated with
a cyclin D1 monoclonal antibody or normal rabbit serum. As a control,
10% of the whole cell lysate was also loaded in parallel for direct
Western analysis (Fig. 2A,
lanes 1, 4, 7, and
10). The protein complexes were resolved by SDS-PAGE and
analyzed by immunoblot. Both MCM3 and MCM7 were detected in cyclin D1
precipitates (Fig. 2A, lanes 6 and
12) but not in a normal rabbit serum precipitation (lanes 5 and 11). Although MCM2 and
MCM6 were expressed (lanes 1 and 7),
they did not associate with cyclin D1 (lanes 3 and 9). These results demonstrate that cyclin D1 can bind to
MCM7 in vitro and associate with both MCM7 and MCM3 in
intact cells. The failure of cyclin D1 to bind MCM3 in vitro
but associate in cells suggests that D1-MCM3 binding requires an as yet
unidentified protein or post-translational modification.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 2.
Cyclin D1 binds MCM7 in intact cells.
A, D1 binds MCM7 and MCM3 in Sf9 cells. Whole cell
lysates were prepared from Sf9 insect cells infected with
baculovirus encoding MCM2, MCM3, MCM6, or HA-MCM7 and Flag-D1. Ten
percent of the immunoprecipitated protein was directly loaded
(lanes 1, 4, 7, and
10; ), or lysates were precipitated with either
normal rabbit serum (lanes 2, 5,
8, and 11; NRS) or a cyclin
D1-specific monoclonal antibody (lanes 3,
6, 9, and 12; D1). Protein
complexes were resolved on denaturing polyacrylamide gels and
visualized by immunoblot with antibodies specific for MCM2, MCM3, MCM6,
MCM7, or cyclin D1 (D1). B, schematic
representation of cyclin D1 deletion mutants used in C. C, residues 142-253 of cyclin D1 mediate association with
MCM7. Sf9 insect cells were infected with baculoviruses encoding
HA-MCM7 (M7) along with Flag-D1 (FD1)
(lane 2), untagged cyclin D1 (mD1)
(lane 3), Flag-D1 XMN ( XMN)
(lane 4), or Flag D1 1-99
( 1-99) (lane 5). Sf9
lysates were immunoprecipitated with either normal rabbit serum
(lane 1) or a cyclin D1-specific antibody
(lanes 2-5). Proteins were visualized by
immunoblot using antibodies specific for HA-MCM7 or cyclin D1 followed
by enhanced chemiluminescence.
|
|
To identify the region of cyclin D1 required for MCM7 association, we
expressed a series of cyclin D1 mutants (Fig. 2B) along with
MCM7 in Sf9 cells. Protein complexes were precipitated with a
monoclonal antibody specific for either the Flag epitope or murine
cyclin D1. MCM7·D1 binding was monitored by immunoblot with
antibodies specific for MCM7 or for cyclin D1. Cyclin D1 mutants and
wild-type proteins were present in equivalent amounts (Fig.
2C, lower panel, lanes
2-5). MCM7 co-precipitated with Flag-D1 (Fig.
2C, lane 2), untagged D1
(lane 3), and a mutant cyclin D1 wherein the
NH2-terminal 99 residues were deleted (lane
4). In contrast, MCM7 binding to cyclin D1 containing a
deletion of residues 142-253 was significantly reduced
(lane 5). The deletion of residues 142-253 in
cyclin D1 removes a portion of the cyclin box rendering this mutant
catalytically inactive (data not shown). Deletion of the
carboxyl-terminal 61 residues of cyclin D1 also failed to inhibit MCM7
binding (data not shown). We conclude that cyclin D1 residues between
142 and 253 mediate MCM7 association.
Cyclin D1 Associates with Chromatin-bound MCM7--
The MCM
helicase is loaded onto chromatin during G1 phase at
replication origins and remains chromatin bound through the initiation of S phase (11, 27-30). Because cyclin D1 can associate with MCM7, we
determined whether cyclin D1 was integrated into chromatin-bound complexes during G1 phase. NIH-3T3 cells synchronized in
G0 by contact inhibition and serum starvation were
stimulated to reenter the cell cycle. Cells were collected at various
intervals thereafter and separated into soluble or chromatin-enriched
protein fractions (31). Protein from chromatin-enriched fractions was
resolved on denaturing polyacrylamide gels, and cyclin D1 levels were
assessed by immunoblot. Cyclin D1 was incorporated into chromatin-bound complexes by 6 h following serum stimulation with levels peaking at
18 h (Fig. 3A). S phase
entry was detected at 18 h, as determined by bromodeoxyuridine
incorporation (data not shown). Although this result demonstrates that
cyclin D1 does accumulate in chromatin-bound complexes in a cell
cycle-dependent fashion, it remained possible that this
apparent regulation stems from cyclin availability, given that cyclin
D1 is expressed as a delayed early gene during cell cycle reentry (32).
To rule out the possibility that regulated chromatin binding by cyclin
D1 simply reflected protein availability, we examined cyclin D1
chromatin association in cells that constitutively overexpress
Flag-tagged cyclin D1 independently of mitogenic stimuli (20, 33).
D1-3T3 cells synchronized and treated as above were collected at
various intervals after release and fractionated for chromatin-bound
proteins. Protein levels were assessed by immunoblot analysis with
antibodies specific for cyclin D1, CDK4, MCM7, and MCM3. In D1-3T3
cells, cyclin D1 (Fig. 3B, top panel) and CDK4 (second panel) were incorporated into
chromatin-associated protein complexes by 9 h. Available soluble
components of the pre-RC, MCM3 (bottom panel) and
MCM7 (third panel), were redistributed from a
soluble protein fraction into chromatin-bound complexes with kinetics
similar to those for the cyclin D1/CDK4 holoenzyme. These results
demonstrate that cyclin D1/CDK4 complexes are incorporated into
chromatin-bound protein complexes in a regulated manner that temporally
mimics that of the pre-RC.

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 3.
Cyclin D1 binds to chromatin in a cell
cycle-dependent manner. A, association of
endogenous cyclin D1 with chromatin during G1. NIH-3T3
cells synchronized in G0 by serum starvation and contact
inhibition were stimulated to reenter the cell cycle with complete
medium and collected at the indicated time points following release.
Cells were lysed in CSK buffer, and chromatin pellets were incubated
with DNase I, to release chromatin-bound proteins. Equivalent
concentrations of protein were resolved by SDS-PAGE, transferred to
nitrocellulose membrane, and blotted with antibodies specific for
cyclin D1 (D1). B, D1/CDK4 chromatin association
mirrors that of MCM chromatin binding. D1-3T3 cells were synchronized
in G0 and stimulated to reenter the cell cycle as described
in A. Cells were lysed and chromatin-bound proteins were
collected as described in A. Equivalent concentrations of
soluble and chromatin-bound protein were resolved by electrophoresis
and transferred to nitrocellulose and blotted with antibodies specific
for cyclin D1 (D1), CDK4 (K4), MCM7
(M7), and MCM3 (M3).
|
|
We next assessed whether chromatin-bound cyclin D1 co-localized with
MCM7. NIH-3T3 cells were transfected with plasmids encoding Flag-D1,
CDK4, and MCM7. Cells were collected and either immediately fixed (Fig.
4A, whole
cell) or subjected to in situ extractions with
CSK+ buffer to remove soluble protein, leaving chromatin and
chromatin-bound proteins intact prior to fixation (Fig. 4A, Chrom. Bound Protein). Cyclin D1 was
visualized with the M2 monoclonal antibody and MCM7 with a rabbit
antibody specific for MCM7. In cells that had not been extracted with
detergent, both MCM7 (Fig. 4A, panel
a) and cyclin D1 (panel b) were
localized to nuclear and cytoplasmic compartments (panel
c). Following in situ extraction, cyclin D1
(panel f) and MCM7 (panel
e) were exclusively nuclear and co-localized to nuclear foci
(panel g). Both cyclin D1 (panel j)
and MCM7 (panel i) staining were absent in cells
treated with nuclease, demonstrating that retention of staining
following detergent extraction is dependent upon intact chromatin.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 4.
The cyclin D1/CDK4 active holoenzyme binds
MCM7 on chromatin. A, cyclin D1 and MCM7
co-localize on chromatin. NIH-3T3 cells were transiently transfected
with plasmids expressing HA-MCM7, Flag-D1, and CDK4. Cells were either
fixed (Whole Cell) or subjected to in
situ extraction with CSK+ buffer (Chrom.
Bound Protein) and then stained with a rabbit
anti-MCM7 (M7) antibody or the M2 monoclonal antibody. To
ensure that protein remaining after in situ extraction
required intact chromatin, cells were treated with DNase I
(DNase) prior to incubation with antigen-specific
antibodies. Cells were stained with a monoclonal MCM7 antibody
(M7) and a M2 monoclonal antibody. B, cyclin D1
associates with chromatin-bound MCM7. NIH-3T3 cells synchronized in
G0 by serum starvation and contact inhibition were
stimulated with complete medium and collected 9 h after
stimulation. Cells were subjected to chromatin fractionation, equal
amounts of soluble and chromatin-bound protein were immunoprecipitated
with either normal rabbit serum (lane 1) or a
cyclin D1 monoclonal antibody (lanes 2 and
3), and protein complexes were resolved by SDS-PAGE. Western
blots were performed using antibodies specific for MCM7
(upper panel) and cyclin D1 (lower
panel). C, the catalytically active cyclin
D1/CDK4 kinase is incorporated into chromatin-bound complexes.
D1-T286A-3T3 cells were synchronized in G0 by serum
starvation and contact inhibition. Cells were released and collected 9 h after stimulation. Chromatin fractionations were performed, and equal
levels of chromatin-bound protein were immunoprecipitated with either
normal rabbit serum (lane 1) or a cyclin D1
antibody (lane 2). Immunoprecipitated complexes
were mixed with GST-RB and [ -32P]ATP. Phosphorylated
GST-RB was resolved on a polyacrylamide gel and visualized by
autoradiography.
|
|
To directly address cyclin D1·MCM7 association in vivo,
NIH-3T3 cells synchronized in late G1 phase were collected
and separated into soluble or chromatin-bound protein fractions. These
fractions were precipitated with the cyclin D1 monoclonal antibody, and MCM7 binding was assessed by immunoblot analysis. MCM7 co-precipitated with cyclin D1 from the chromatin fraction (Fig. 4B,
lane 3) but not the soluble fraction
(lane 2). Finally, to determine whether chromatin-associated cyclin D1 is present as a catalytically active kinase, we utilized NIH-3T3 cell lines that overexpress the
constitutively nuclear cyclin D1 mutant (D1-T286A) or wild-type cyclin
D1 to facilitate detection of RB kinase activity. Cyclin D1 proteins were precipitated from extracts containing protein released from chromatin by nuclease digestion and assayed for their ability to
phosphorylate recombinant GST-RB in vitro. Cyclin D1
isolated from chromatin fractions prepared from D1-T286A-3T3 cells
(Fig. 4C, lane 2) and D1-3T3 (data
not shown) phosphorylated recombinant RB, whereas control precipitates
failed to do so (lane 1). Collectively, these
experiments demonstrate that the active cyclin D1/CDK4 holoenzyme is
incorporated into chromatin-bound MCM7 complexes during G1 phase.
Regulation of the MCM7·RB Complex by the Cyclin
D1-dependent Kinase--
The ability of active RB to
oppose G1 phase progression via its capacity to bind to and
repress E2F family members is well documented (1, 17, 34). More
recently, RB has also been found to participate more directly in the
negative regulation of DNA replication via its capacity to bind to MCM7
(18) and form higher order complexes that include both E2F and ORC
(19). Given the capacity of the cyclin D1/CDK4 kinase to inhibit RB activity via phosphorylation-dependent disassociation of
RB/E2F complexes (35), we considered the possibility that active cyclin D1/CDK4 might dissociate RB·MCM7 complexes. Sf9 cells were
infected with baculovirus encoding full-length RB and MCM7 alone or in combination with cyclin D1 and CDK4; cyclin D1 and a catalytically inactive CDK4 mutant, containing an alanine for threonine substitution at residue 172 (CDK4T172A) (36); cyclin E and CDK2; or cyclin D1-T286A
and CDK4. Complexes were precipitated with a MCM7-specific antibody,
and co-precipitating proteins were detected by immunoblot. In the
absence of cyclin D1/CDK4 kinase, RB efficiently co-precipitated with
MCM7 (Fig. 5A, lane
2). RB was also detected in MCM7 precipitates when
co-expressed with catalytically inactive cyclin D1/CDK4T172A (lane 4). In contrast, co-expression of active
cyclin D1/CDK4 (lane 3) or D1-T286A/CDK4
(lane 6) essentially eliminated co-precipitation of MCM7 with RB. Surprisingly, active cyclin E/CDK2 complexes did not
inhibit RB·MCM7 association (lane 5).

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 5.
Cyclin D1/CDK4 activity disassociates an
RB·MCM7 complex. A, cyclin D1/CDK4 dissociates
RB·MCM7 complexes in Sf9 cells. Sf9 cells were infected
with baculovirus encoding RB and MCM7 alone or in combination with
cyclin D1 and CDK4, cyclin D1 and kinase-defective CDK4-T172A, cyclin E
and CDK2, or cyclin D1-T286A and CDK4. Complexes were collected by
precipitation with a MCM7-specific antibody and visualized by
immunoblot with antibodies that recognized RB (top
panel), MCM7 (middle panel), or cyclin
D1 (lower panel) followed by enhanced
chemiluminescence. B, cyclin D1/CDK4 disassociates RB·MCM7
complexes. RB·MCM7 complexes were purified from programmed Sf9
cells by precipitation with an RB-specific antibody and mixed with
control, no kinase (lane 1), cyclin D1/CDK4
(lane 2), or cyclin E/CDK2 (lane
3) along with [ -32P]ATP and incubated at
30 °C for 30 min. Complexes were then washed extensively with
buffer, denatured, and resolved by SDS-PAGE. Following transfer to
nitrocellulose membrane, phosphorylated RB was visualized by
autoradiography (top panel). Total RB
(middle panel) and MCM7 (bottom
panel) were visualized by immunoblot analysis with
appropriate antibodies.
|
|
Although these results are consistent with the idea that cyclin D1/CDK4
phosphorylation triggers RB·MCM7 dissociation, we could not rule out
the possibility that phosphorylation might simply prevent the initial
RB·MCM7 interaction. To distinguish between these two possibilities,
RB·MCM7 complexes were purified from Sf9 cells using an
RB-specific antibody coupled to protein A-Sepharose. Purified
recombinant cyclin D1/CDK4 or cyclin E/CDK2 was combined with
equivalent concentrations of bound RB·MCM7 (Fig. 5B,
middle panel) along with
[
-32P]ATP. Following incubation at 30 °C for 30 min, complexes were washed extensively to remove dissociated MCM7. Both
cyclin D1/CDK4 (lane 2, upper
panel) and cyclin E/CDK2 (lane 3,
upper panel) phosphorylated RB. However, although
MCM7 remained associated with RB in the presence of active cyclin
E/CDK2 kinase (compare lanes 1 and 3 in bottom panel), phosphorylation of RB by cyclin D1/CDK4 efficiently dissociated the RB·MCM7 complex (lane
2, bottom panel). These data
demonstrate that the cyclin D1-dependent kinase can promote
dissociation of RB·MCM7 complexes both in vitro and in
intact cells.
Work from two different groups suggests RB functions to inhibit DNA
replication through association with chromatin-bound components of the
replication complex (18, 19, 37). Given this, we considered that cyclin
D1-dependent dissociation of RB from MCM7 in
vivo might result in the removal of RB from a chromatin context. To address this issue, RB null (RB
/
) MEFs were transiently
transfected with vectors encoding RB alone (Fig.
6A, panels
a, d, and g); RB, Flag-D1, and CDK4
(panels b, e, and h); or
RB, Flag-D1, and catalytically inactive CDK4-K35M (panels
c, f, and i). Transfected cells were
subjected to in situ extraction, leaving intact chromatin and chromatin-bound protein, and subsequently stained with the M2
antibody and a polyclonal RB antibody. Cells subjected to in situ extraction illustrate that both active (Fig. 6A,
panel h) and inactive cyclin D1/CDK4
(panel i) complexes are associated with chromatin
but that only active D1/CDK4 kinase removed RB from chromatin (compare
panels e and f). RB not only binds
MCM7 but other chromatin-bound tethers such as the transcription factor E2F, and complete liberation of RB-dependent repression of
E2F is not an individual activity of the cyclin D1/CDK4 kinase but instead a sequential activity of D1/CDK4 and cyclin E/CDK2 (38). To
determine whether cyclin E/CDK2 could also remove chromatin-bound RB,
we transfected RB
/
MEFs with vectors encoding RB, Myc-tagged cyclin
E and CDK2. Cells were either directly fixed (Fig. 6B, panels b, d, and f) or
extracted of soluble protein with detergent and fixed
(panels a, c, and e). Cells
were stained with both the 9E10 monoclonal antibody and the RB-specific
antibody. Consistent with the inability of cyclin E/CDK2 to dissociate
RB·MCM7 complexes in vitro, overexpressed cyclin E/CDK2
did not promote the removal of RB from chromatin (Fig. 5B,
panel d). These results demonstrate that the
active cyclin D1/CDK4 kinase can promote RB·MCM7 dissociation and
thereby catalyze its dissociation from chromatin.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 6.
Cyclin D1/CDK4 enforces removal of RB from
chromatin. A, cyclin D1 expression removes RB from the
chromatin fraction. Active cyclin D1/CDK4 removes RB from chromatin.
RB / MEFs proliferating on glass coverslips were
transfected with a plasmid encoding wild-type RB alone
(panels a, d, and g) or in
combination with vectors encoding Flag-D1 and CDK4 (panels
b, e, and h), or Flag-D1 and
catalytically inactive CDK4-K35M (panels c,
f, and i). Cells were subjected to an in
situ extraction leaving intact chromatin and chromatin-bound
protein and subsequently stained with a RB-specific antibody
(RB) (panels d-f), a M2 monoclonal
antibody (D1) (panels g-i), and
Hoechst dye (panels a-c). B, cyclin
E/CDK2 activity is not sufficient to remove RB from chromatin. NIH-3T3
cells were transfected with vectors encoding RB, Myc-cyclin E, and
CDK2. Cells were collected and directly fixed (panels
b, d, and f) or subjected to in
situ extraction prior to fixation (panels a,
c, and e) and then stained with a RB-specific
antibody (RB) and an antibody specific for the Myc tag of
cyclin E.
|
|
 |
DISCUSSION |
Identification of MCM7 as a Cyclin D1-binding Protein--
The
primary function of the cyclin D1-dependent kinase is to
initiate the phosphorylation-dependent inactivation of RB
during G1 progression. Numerous studies have been
undertaken in an effort to elucidate the critical targets of the cyclin
D1-dependent kinase. Cyclin D1 has been reported to bind to
DNA-binding transcription factors such as DMP1 (39), the estrogen
receptor (40) and to DNA-modifying proteins such as P/CAF (41). More
recently, cyclin D1 was also shown to weakly associate with the ORC1
subunit of the origin recognition complex (42). The potential
contribution of these interactions to cell cycle progression remains
unclear. We therefore utilized a yeast two-hybrid screen using cyclin
D1 as bait to identify potential targets of cyclin D1. This screen revealed the pre-RC component MCM7 as a novel cyclin D1-binding protein. Our data support a direct interaction between the COOH terminus of MCM7 and residues 142-253 of cyclin D1. This region of D1
also mediates an interaction with the DMP1 transcription factor (39),
demonstrating that this region of cyclin D1 mediates binding with
several distinct DNA-binding proteins. In addition, our data
demonstrate that catalytically active cyclin D1/CDK4 is incorporated
into chromatin-bound MCM7 complexes during G1 progression.
Although cyclin D1 associates with MCM7 on chromatin during
G1, we found that it is removed from chromatin at the onset of S phase (data not shown), after which it is transported to the
cytoplasm via CRM1-dependent nuclear export (20, 33). The
previous demonstration that constitutively nuclear cyclin D1 has an
increased propensity to promote cell transformation suggests that,
although nuclear cyclin D1/CDK4 plays a regulatory role in the
maturation of the pre-RC during G1, nuclear D1/CDK4 is
deleterious for S phase progression. Although MCM7 is not a substrate
for cyclin D1/CDK4 (negative data not shown), our data do suggest that
cyclin D1/CDK complexes regulate MCM7 function through RB (see below).
This does not rule out the possibility that an intact hexameric MCM
complex is a substrate for cyclin D1/CDK4. This possibility is
currently being explored.
Regulation of the MCM7·RB Complex by the Cyclin
D1-dependent Kinase--
RB is widely viewed as the
essential gatekeeper of the restriction point, ensuring the cell has
prepared its replicative machinery prior to progression into S phase
(1). RB indirectly regulates cell proliferation and S phase entry via
binding to and suppression of E2F-dependent gene expression
(34, 43). E2F complexes activate a large body of cell cycle genes
needed for further cell cycle progression including dihydrofolate
reductase, thymidine kinase, cyclin A, cyclin E, cdk2, and cdc2
(44-51). In addition to E2F family members, the MCM7 protein is also
targeted by RB (18). RB binds to the COOH terminus of MCM7 and via this
interaction directly prevents DNA replication (18). Given that MCM7 is
not a cyclin D1/CDK4 substrate and, like E2F, is regulated by RB family members, we determined the ability of the cyclin D1/CDK4 kinase to
regulate the RB·MCM7 interactions. Our data revealed that the cyclin
D1/CDK4 kinase could specifically trigger the dissociation of RB·MCM7
complexes. These data introduce a new possible regulatory mechanism
whereby D1/CDK4 activity facilitates transition through the restriction
point and promotes S phase entry.
Collectively, the data presented herein, along with previously
published work (18), suggest that the cyclin D-RB-Ink4 pathway is not
simply a mechanism that ensures correct temporal regulation of gene
expression, but one that also directly regulates the initiation of DNA
replication. This does not imply that the cyclin D1/CDK4 activity is
sufficient to drive cells into S phase. The activity of cyclin A/CDK2
is necessary for both S phase entry (52) and inhibition of
re-replication (53-56). Our data demonstrate that cyclin D1
specifically negates RB activity at the pre-RC, thereby setting the
"trigger" for initiation of DNA replication. The trigger is
released upon activation of cyclin E/CDK2 and CDC7/DBF4 (12-16, 57,
58).
The demonstration that cyclin E/CDK2 and cyclin A/CDK2 (data not shown)
cannot dissociate RB·MCM7 complexes suggests that this is an
essential function for the cyclin D-dependent kinase. However, in the context of the whole organism, there is greater potential for functional overlap between the cyclin complexes than what
can be reconstituted in vitro. For example, cyclin D1
/
mice are viable (59). In this case, cyclins D2 and D3 likely serve the
role of cyclin D1. However, overexpression of cyclin E and CDC6 can
induce S phase entry in the absence of mitogenic stimulation (60).
Because these experiments are performed in the absence of mitogens, the
cyclin D-dependent kinase is not activated and the cyclin
E/CDK2 kinase along with CDC6 is driving S phase entry. If cyclin
E/CDK2 cannot drive RB·MCM7 dissociation, how would it drive S phase
entry? One possibility is that, under conditions where cyclin E is
overexpressed at high levels, it will promote RB·MCM7 dissociation.
Alternatively, S phase entry under these conditions may reflect the
ability of cyclin E to drive E2F activation (52), which will in turn
promote increased expression of MCMs and thereby override
RB-dependent inhibition. Although our data are consistent
with a model wherein cyclin D1-dependent kinase targets
pre-RC through RB, we cannot rule out the existence of other cyclin D1
substrates within the chromatin-bound complexes.
 |
ACKNOWLEDGEMENTS |
We thank Charles J. Sherr (St. Jude
Children's Research Hospital, Memphis, TN) for providing NIH-3T3 cells
and RB
/
MEFs, Rob Lewis (Eppley Institute, University of Nebraska
Medical Center, Omaha, NE) for the 293 cDNA library, Mike
Olson and Hiroshi Kimura for the cDNAs encoding MCM2-6, and Bruce
Clurman (Fred Hutchinson Cancer Center, Seattle, WA) for Myc-tagged
cyclin E. We gratefully acknowledge the excellent technical assistance
of Ronald Rimerman.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grant CA93237 (to J. A. D.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. E-mail:
adiehl@mail.med.upenn.edu.
Published, JBC Papers in Press, January 7, 2003, DOI 10.1074/jbc.M212088200
 |
ABBREVIATIONS |
The abbreviations used are:
CDK, cyclin-dependent kinase;
MEF, murine embryonic fibroblast;
MCM, minichromosome maintenance;
ORC, origin recognition complex;
RB, retinoblastoma protein;
Pipes, 1,4-piperazinediethanesulfonic acid;
pre-RC, pre-replication complex;
HA, hemagglutinin;
IP, immunoprecipitation;
HRP, horseradish peroxidase;
GST, glutathione
S-transferase.
 |
REFERENCES |
1.
|
Weinberg, R. A.
(1995)
Cell
81,
323-330[Medline]
[Order article via Infotrieve]
|
2.
|
Sherr, C. J.,
and Roberts, J. M.
(1999)
Genes Dev.
13,
1501-1512[Free Full Text]
|
3.
|
Bell, S. P.,
and Stillman, B.
(1992)
Nature
357,
128-134[CrossRef][Medline]
[Order article via Infotrieve]
|
4.
|
Lipford, J. R.,
and Bell, S. P.
(2001)
Mol. Cell
7,
21-30[Medline]
[Order article via Infotrieve]
|
5.
|
Santocanale, C.,
and Diffley, J. F.
(1996)
EMBO J.
15,
6671-6679[Abstract]
|
6.
|
Maiorano, D.,
Moreau, J.,
and Mechali, M.
(2000)
Nature
404,
622-625[CrossRef][Medline]
[Order article via Infotrieve]
|
7.
|
Chong, J. P.,
Mahbubani, H. M.,
Khoo, C. Y.,
and Blow, J. J.
(1995)
Nature
375,
418-421[CrossRef][Medline]
[Order article via Infotrieve]
|
8.
|
Tanaka, T.,
Knapp, D.,
and Nasmyth, K.
(1997)
Cell
90,
649-660[Medline]
[Order article via Infotrieve]
|
9.
|
Yan, H.,
Merchant, A. M.,
and Tye, B. K.
(1993)
Genes Dev.
7,
2149-2160[Abstract]
|
10.
|
Koonin, E. V.
(1993)
Nucleic Acids Res.
21,
4847[Medline]
[Order article via Infotrieve]
|
11.
|
Labib, K.,
Tercero, J. A.,
and Diffley, J. F.
(2000)
Science
288,
1643-1647[Abstract/Free Full Text]
|
12.
|
Lei, M.,
Kawasaki, Y.,
Young, M. R.,
Kihara, M.,
Sugino, A.,
and Tye, B. K.
(1997)
Genes Dev.
11,
3365-3374[Abstract/Free Full Text]
|
13.
|
Brown, G. W.,
and Kelly, T. J.
(1998)
J. Biol. Chem.
273,
22083-22090[Abstract/Free Full Text]
|
14.
|
Jiang, W.,
McDonald, D.,
Hope, T. J.,
and Hunter, T.
(1999)
EMBO J.
18,
5703-5713[Abstract/Free Full Text]
|
15.
|
Jackson, A. L.,
Pahl, P. M.,
Harrison, K.,
Rosamond, J.,
and Sclafani, R. A.
(1993)
Mol. Cell. Biol.
13,
2899-2908[Abstract]
|
16.
|
Yoon, H. J.,
Loo, S.,
and Campbell, J. L.
(1993)
Mol. Biol. Cell
4,
195-208[Abstract]
|
17.
|
Chellappan, S. P.,
Hiebert, S.,
Mudryj, M.,
Horowitz, J. M.,
and Nevins, J. R.
(1991)
Cell
65,
1053-1061[Medline]
[Order article via Infotrieve]
|
18.
|
Sterner, J. M.,
Dew-Knight, S.,
Musahl, C.,
Kornbluth, S.,
and Horowitz, J. M.
(1998)
Mol. Cell. Biol.
18,
2747-2757
|
19.
|
Bosco, G.,
Du, W.,
and Orr-Weaver, T. L.
(2001)
Nat. Cell Biol.
3,
289-295[CrossRef][Medline]
[Order article via Infotrieve]
|
20.
|
Diehl, J. A.,
Cheng, M.,
Roussel, M. F.,
and Sherr, C. J.
(1998)
Genes Dev.
12,
3499-3511[Abstract/Free Full Text]
|
21.
| Summers, M. D., and Smith, G. E. (1987) Tex. Agric.
Exp. St. Bull. 1555
|
22.
|
Rimerman, R. A.,
Gellert-Randleman, A.,
and Diehl, J. A.
(2000)
J. Biol. Chem.
275,
14736-14742[Abstract/Free Full Text]
|
23.
|
Kiyono, T.,
Fujita, M.,
Hayashi, Y.,
and Ishibashi, M.
(1996)
Biochim. Biophys. Acta
1307,
31-34[Medline]
[Order article via Infotrieve]
|
24.
|
Lee, J. K.,
and Hurwitz, J.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
54-59[Abstract/Free Full Text]
|
25.
|
Lee, J. K.,
and Hurwitz, J.
(2000)
J. Biol. Chem.
275,
18871-18878[Abstract/Free Full Text]
|
26.
|
You, Z.,
Komamura, Y.,
and Ishimi, Y.
(1999)
Mol. Cell. Biol.
19,
8003-8015[Abstract/Free Full Text]
|
27.
|
Diffley, J. F.,
Cocker, J. H.,
Dowell, S. J.,
and Rowley, A.
(1994)
Cell
78,
303-316[Medline]
[Order article via Infotrieve]
|
28.
|
Mendez, J.,
and Stillman, B.
(2000)
Mol. Cell. Biol.
20,
8602-8612[Abstract/Free Full Text]
|
29.
|
Tye, B. K.,
and Sawyer, S.
(2000)
J. Biol. Chem.
275,
34833-34836[Free Full Text]
|
30.
|
Tye, B. K.
(1999)
Annu. Rev. Biochem.
68,
649-686[CrossRef][Medline]
[Order article via Infotrieve]
|
31.
|
Burke, T. W.,
Cook, J. G.,
Asano, M.,
and Nevins, J. R.
(2001)
J. Biol. Chem.
276,
15397-15408[Abstract/Free Full Text]
|
32.
|
Matsushime, H.,
Roussel, M. F.,
Ashmun, R. A.,
and Sherr, C. J.
(1991)
Cell
65,
701-713[Medline]
[Order article via Infotrieve]
|
33.
|
Alt, J. R.,
Cleveland, J. L.,
Hannink, M.,
and Diehl, J. A.
(2000)
Genes Dev.
14,
3102-3114[Abstract/Free Full Text]
|
34.
|
Nevins, J. R.
(1992)
Science
258,
424-429[Medline]
[Order article via Infotrieve]
|
35.
|
Kato, J.,
Matsushime, H.,
Hiebert, S. W.,
Ewen, M. E.,
and Sherr, C. J.
(1993)
Genes Dev.
7,
331-342[Abstract]
|
36.
|
Kato, J.-Y.,
Matsuoka, M.,
Strom, D. K.,
and Sherr, C. J.
(1994)
Mol. Cell. Biol.
14,
2713-2721[Abstract]
|
37.
|
Kennedy, B. K.,
Barbie, D. A.,
Classon, M.,
Dyson, N.,
and Harlow, E.
(2000)
Genes Dev.
14,
2855-2868[Abstract/Free Full Text]
|
38.
|
Lundberg, A. S.,
and Weinberg, R. A.
(1998)
Mol. Cell. Biol.
18,
753-761[Abstract/Free Full Text]
|
39.
|
Inoue, K.,
and Sherr, C. J.
(1998)
Mol. Cell. Biol.
18,
1590-1600[Abstract/Free Full Text]
|
40.
|
Neuman, E.,
Ladha, M. H.,
Lin, N.,
Upton, T. M.,
Miller, S. J.,
DiRenzo, J.,
Pestell, R. G.,
Hinds, P. W.,
Dowdy, S. F.,
Brown, M.,
and Ewen, M. E.
(1997)
Mol. Cell. Biol.
17,
5338-5347[Abstract]
|
41.
|
McMahon, C.,
Suthiphongchai, T.,
DiRenzo, J.,
and Ewen, M. E.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
5382-5387[Abstract/Free Full Text]
|
42.
|
Laman, H.,
Coverley, D.,
Krude, T.,
Laskey, R.,
and Jones, N.
(2001)
Mol. Cell. Biol.
21,
624-635[Abstract/Free Full Text]
|
43.
|
Nevins, J. R.
(2001)
Hum. Mol. Genet.
10,
699-703[Abstract/Free Full Text]
|
44.
|
Wade, M.,
Kowalik, T. F.,
Mudryj, M.,
Huang, E. S.,
and Azizkhan, J. C.
(1992)
Mol. Cell. Biol.
12,
4364-4374[Abstract]
|
45.
|
Ren, B.,
Cam, H.,
Takahashi, Y.,
Volkert, T.,
Terragni, J.,
Young, R. A.,
and Dynlacht, B. D.
(2002)
Genes Dev.
16,
245-256[Abstract/Free Full Text]
|
46.
|
Ishida, S.,
Huang, E.,
Zuzan, H.,
Spang, R.,
Leone, G.,
West, M.,
and Nevins, J. R.
(2001)
Mol. Cell. Biol.
14,
4684-4699[CrossRef]
|
47.
|
Furukawa, Y.,
Terui, Y.,
Sakoe, K.,
Ohta, M.,
and Saito, M.
(1994)
J. Biol. Chem.
269,
26249-26258[Abstract/Free Full Text]
|
48.
|
Ohtani, K.,
DeGregori, J.,
and Nevin, J. R.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
12146-12150[Abstract]
|
49.
|
Schulze, A.,
Zerfass, K.,
Spitkovsky, D.,
Middendorp, S.,
Berges, J.,
Helin, K.,
Jansen-Durr, P.,
and Henglein, B.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
11264-11268[Abstract]
|
50.
|
Botz, J.,
Zerfass-Thome, K.,
Spitkovsky, D.,
Delius, H.,
Vogt, B.,
Eilers, M.,
Hatzigeorgiou, A.,
and Jansen-Durr, P.
(1996)
Mol. Cell. Biol.
16,
3401-3409[Abstract]
|
51.
|
Ogris, E.,
Rotheneder, H.,
Mudrak, I.,
Pichler, A.,
and Wintersberger, E.
(1993)
J. Virol.
67,
1765-1771[Abstract]
|
52.
|
Coverley, D.,
Laman, H.,
and Laskey, R. A.
(2002)
Nat. Cell Biol.
4,
523-528[CrossRef][Medline]
[Order article via Infotrieve]
|
53.
|
Petersen, B. O.,
Lukas, J.,
Sorensen, C. S.,
Bartek, J.,
and Helin, K.
(1999)
Genes Dev.
18,
396-410
|
54.
|
Mahbubani, H. M.,
Chong, J. P. J.,
Chevalier, S.,
Thommes, P.,
and Blow, J. J.
(1997)
J. Cell Biol.
136,
125-135[Abstract/Free Full Text]
|
55.
|
Izumi, M.,
Yatagai, F.,
and Hanaoka, F.
(2001)
J. Biol. Chem.
276,
48526-48531[Abstract/Free Full Text]
|
56.
|
Ishimi, Y.,
and Komamura-Kohno, Y.
(2001)
J. Biol. Chem.
276,
34428-34433[Abstract/Free Full Text]
|
57.
|
Nasmyth, K.
(1993)
Curr. Opin. Cell Biol.
5,
166-179[Medline]
[Order article via Infotrieve]
|
58.
|
Kitada, K.,
Johnston, L. H.,
Sugino, T.,
and Sugino, A.
(1992)
Genetics
131,
21-29[Abstract/Free Full Text]
|
59.
|
Sicinski, P.,
Donaher, J. L.,
Parker, S. B.,
Li, T.,
Fazeli, A.,
Gardner, H.,
Haslam, S. Z.,
Bronson, R. T.,
Elledge, S. J.,
and Weinberg, R. A.
(1995)
Cell
82,
621-630[Medline]
[Order article via Infotrieve]
|
60.
|
Cook, J. G.,
Park, C.,
Burke, T. W.,
Leone, G.,
DeGregori, J.,
Engel, A.,
and Nevins, J. R.
(2002)
Proc. Natl. Acad. Sci. U. S. A.
99,
1347-1352[Abstract/Free Full Text]
|
Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.